AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

被引：0

作者：

Schumann, C. ^{[1
]}

Heymach, J. V. ^{[2
]}

Harpole, D. ^{[3
]}

Mitsudomi, T. ^{[4
]}

Taube, J. M. ^{[5
]}

Galffy, G. ^{[6
]}

Hochmair, M. ^{[7
]}

Winder, T. ^{[8
]}

Zukov, R. ^{[9
]}

Garbaos, G. ^{[10
]}

Gao, S. ^{[11
]}

Kuroda, H. ^{[12
]}

You, J. ^{[13
]}

Lee, K. -Y. ^{[14
]}

Antonuzzo, L. ^{[15
]}

Aperghis, M. ^{[16
]}

Doherty, G. J. ^{[16
]}

Mann, H. ^{[16
]}

Fouad, T. M. ^{[17
]}

Reck, M. ^{[18
]}

Weissinger, F. ^{[19
]}

机构：

[1] Clin Allgau Kempten & Immenstadt, Thorac Surg, Kempten, Germany

[2] MD Anderson Canc Ctr, Houston, TX USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Kindai Univ, Fac Med, Osaka, Japan

[5] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA

[6] Pest Cty Pulmonol Hosp, Torokbalint, Hungary

[7] Klin Floridsdorf, Vienna, Austria

[8] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[9] Krasnoyarsk State Med Univ, Krasnoyarsk, Russia

[10] Fdn Estudios Clin, Santa Fe, NM USA

[11] Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China

[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[13] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[14] Shuang Ho Hosp, New Taipei, Taiwan

[15] Careggi Univ Hosp, Florence, Italy

[16] AstraZeneca, Cambridge, England

[17] AstraZeneca, New York, NY USA

[18] Lung Clin Grosshansdorf, Grosshansdorf, Germany

[19] Evangel Klinikum Bethel, Bielefeld, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V47

引用

页码：8 / 9

页数：2

共 50 条

[1] Surgical Outcomes with Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)
Mitsudomi, T.
Heymach, J. V.
Reck, M.
Taube, J. M.
Gao, S.
Horio, Y.
You, J.
Li, G.
Van Luong, D.
Saeteng, S.
Tanaka, F.
Kulesza, G.
Watzka, S. B.
Urban, L.
Szalai, Z.
Akamatsu, H.
Kang, J. -H.
Orlandi, F. J.
Mukhametshina, G. Z.
Pircher, A.
Teixeira, C. H. A.
Aperghis, M.
Doherty, G. J.
Doake, R.
Fouad, T. M.
Harpole, D.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S71 - S72
[2] Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
He, J.
Gao, S.
Reck, M.
Harpole, D.
Mitsudomi, T.
Taube, J. M.
Lee, K. -Y.
Horio, Y.
Runglodvatana, Y.
Aperghis, M.
Doherty, G. J.
Laud, P. J.
Fouad, T. M.
Heymach, J. V.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S72 - S73
[3] The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
Heymach, J.
Taube, J.
Mitsudomi, T.
Harpole, D.
Aperghis, M.
Trani, L.
Powell, M.
Dennis, P.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S625 - S626
[4] Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
Lee, Jiyun
Cho, Jaeho
Lee, Chang
Lee, Chang Young
Lee, Jin Gu
Kim, Dae Joon
Shim, Hyo Sup
Lim, Sun Min
Kim, Hye Ryun
Cho, Byoung Chul
Hong, Min Hee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC
Reck, Martin
Nadal, Ernest
Girard, Nicolas
Filippi, Andrea R.
Martin, Linda W.
Gay, Carl M.
Petersen, Cordula
Gale, Davina
Emeribe, Ugochinyere A.
Georgoulia, Nefeli
Perez, Ignacio E. Diaz
Spicer, Jonathan D.
CLINICAL LUNG CANCER, 2024, 25 (06)
[6] A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
Powles, T. B.
van der Heijden, M. S.
Galsky, M. D.
Al-Ahmadie, H.
Meeks, J. J.
Nishiyama, H.
Vu, T. Q.
Antonuzzo, L.
Wiechno, P.
Atduev, V.
Kann, A. G.
Kim, T-H.
Rodriguez, C. Suarez
Chang, C-H.
Roghmann, F.
Ozguroglu, M.
Armstrong, J.
Ho, S.
Hois, S.
Catto, J.
ANNALS OF ONCOLOGY, 2024, 35 : 1271 - 1271
[7] Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial
Heymach, John, V
Mitsudomi, Tetsuya
Harpole, David
Aperghis, Mike
Jones, Stephanie
Mann, Helen
Fouad, Tamer M.
Reck, Martin
CLINICAL LUNG CANCER, 2022, 23 (03) : E247 - E251
[8] Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
Li, J.
Li, Q.
Lu, S.
Jiang, L.
Li, L.
Xie, S. -H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S158 - S159
[9] A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.
Kim, Hyung-Don
Ryu, Min-Hee
Park, Young Soo
Lee, Jong Seok
Kang, Yoon-Koo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 408 - 408
[10] A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
Li, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1049 - S1050

← 1 2 3 4 5 →